Search

Displaying results 2601 - 2610 of 7602 in total
  1. Drug

    Oxyquinoline

    go.drugbank.com/drugs/DB11145
    ApprovedInvestigationalVet approved

    It is used as a stabilizer for hydrogen peroxide, where it is sometimes added in cosmetic products.

    Categories: Antiinfectives and Antiseptics for Local Oral Treatment
  2. Drug

    Pargyline

    go.drugbank.com/drugs/DB01626
    Approved

    Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  3. Drug

    Paricalcitol

    go.drugbank.com/drugs/DB00910
    ApprovedInvestigational

    Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

    Synonyms: 19-Nor-1alpha,25-dihydroxyvitamin D2Products: PARITOL 5MCG/ML POR 1 ML SOLUCIÓN INYECTABLE
  4. Drug

    Tenapanor

    go.drugbank.com/drugs/DB11761
    ApprovedInvestigational

    In October 2023, tenapanor was approved for the treatment of chronic kidney disease.[L48511] … Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C).

    Categories: Drugs for Constipation
  5. Drug

    Cystine

    go.drugbank.com/drugs/DB00138
    ApprovedInvestigationalNutraceuticalWithdrawn

    Two molecules of cysteine are joined together by a disulfide bridge to form cystine.

  6. Drug

    Raxibacumab

    go.drugbank.com/drugs/DB08902
    ApprovedInvestigational

    Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. Raxibacumab is produced by recombinant DNA tech...

    Categories: Antiinfectives for Systemic Use
  7. Drug

    Zanidatamab zovodotin

    go.drugbank.com/drugs/DB15472
    Experimental

    [L8234] It is being investigated for several indications characterized by HER2 expression including breast and gastric cancers that have progressed or are refractory to existing HER2-targeted therapies … According to Zymeworks, "ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as [ZW25] but armed with a cytotoxic payload."

  8. Drug

    Aminoglutethimide

    go.drugbank.com/drugs/DB00357
    ApprovedWithdrawn

    It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)

  9. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    [L63927] Gedatolisib was approved by the FDA on July 14, 2026, in combination with [fulvestrant], with or without [palbociclib], for adults with HR-positive, HER2-negative locally advanced or metastatic … [L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options.

  10. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    [L44186] In December 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended etranacogene dezaparvovec be granted marketing authorization for the treatment of severe and moderately … [L44161,L44181] Etranacogene dezaparvovec (Hemgenix, CSL Bering LLC) is a gene therapy for the treatment of hemophilia B that provides a new treatment modality for its patients.